PUBLISHER: The Business Research Company | PRODUCT CODE: 1951708
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951708
Digestive and intestinal remedies refer to medications used to treat gastrointestinal conditions such as stomach upset, constipation, and diarrhea. These remedies utilize drug classes including antacids, proton pump inhibitors, and histamine-2 blockers as part of the treatment process.
The main types of digestive and intestinal remedies include digestive medicines, remedies for gastrointestinal complaints, and natural and synthetic agents. Digestive medicines consist of digestive enzymes, which are organic compounds required by the body to support the breakdown and digestion of food. Digestive medicines help manage occasional heartburn, nausea, and upset stomach. These remedies are used across different age groups, including pediatric and adult populations, and are distributed through various channels such as online and offline outlets.
Tariffs have affected the digestive and intestinal remedies market by increasing import costs for raw materials and pharmaceutical intermediates, particularly impacting antacids, proton pump inhibitors, and herbal remedy segments. Regions such as Asia-Pacific and Europe, which rely heavily on imports, are most affected. While production costs have risen, local manufacturers benefit from tariff protection against foreign competition, encouraging domestic innovation and boosting localized supply chains.
The digestive and intestinal remedies market research report is one of a series of new reports from The Business Research Company that provides digestive and intestinal remedies market statistics, including digestive and intestinal remedies industry global market size, regional shares, competitors with a digestive and intestinal remedies market share, detailed digestive and intestinal remedies market segments, market trends and opportunities, and any further data you may need to thrive in the digestive and intestinal remedies industry. This digestive and intestinal remedies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digestive and intestinal remedies market size has grown strongly in recent years. It will grow from $22.28 billion in 2025 to $23.67 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising gastrointestinal disorder prevalence, increasing use of antacids and ppIs, growing awareness of digestive health, expansion of hospital and clinic infrastructure, adoption of herbal remedies.
The digestive and intestinal remedies market size is expected to see strong growth in the next few years. It will grow to $30.43 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to advancements in gut microbiome therapies, integration of ai in digestive health diagnostics, growth of personalized nutrition and supplements, expansion of online pharmaceutical platforms, rising geriatric population with digestive issues. Major trends in the forecast period include personalized digestive health solutions, growth in herbal and natural remedies, increased focus on gut microbiome research, expansion of online pharmacy and e-pharmacy channels, rising awareness of preventive gastrointestinal care.
The rising number of gastrointestinal disorder cases is expected to propel the growth of the digestive and intestinal remedy market going forward. Gastrointestinal disorders are a broad group of conditions, including nausea, vomiting, food poisoning, and diarrhea, that affect the normal functioning of the gastrointestinal (GI) tract. The increasing incidence of these disorders has led to greater demand for digestive and intestinal remedies that can effectively manage and treat gastrointestinal conditions. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, around 26,890 new cases of stomach cancer are projected in the U.S. in 2024, including 16,160 cases among men and 10,730 among women, resulting in approximately 10,880 deaths, with 6,490 in men and 4,390 in women. Therefore, the growing prevalence of gastrointestinal disorders is driving the growth of the digestive and intestinal remedy market.
Major companies operating in the digestive and intestinal remedy market are introducing innovative offerings such as digital platforms to reach broader customer bases, boost sales, and increase revenue. Digital platforms are online, technology-driven systems that support the creation, delivery, and interaction of digital content, services, or products. For instance, in April 2023, Owlstone Medical, a UK-based biotechnology company, launched OMED Health to enable patients to better understand their gut microbiome and actively manage their digestive health. Initially focused on digestive conditions, OMED Health aims to improve the quality of life for individuals experiencing gut-related issues by delivering faster and clearer insights and greater control over their health. In the field of digestive health, breath testing is increasingly recognized as an effective approach for patients to track and manage symptoms. A key differentiator of OMED Health's gut health tests is their ability to identify very small levels of hydrogen and methane gases in breath samples through a convenient at-home collection process. These gases act as important markers of gut health, indicating the presence of specific gastrointestinal conditions and diseases.
In May 2023, Ironwood Pharmaceuticals, a US- and Switzerland-based company focused on gastrointestinal (GI) healthcare, acquired VectivBio Holding AG for an undisclosed amount. Through this acquisition, Ironwood sought to enhance its rare gastrointestinal disease pipeline, particularly by adding apraglutide, a next-generation, long-acting GLP-2 analogue in Phase III development for short bowel syndrome with intestinal failure (SBS-IF). VectivBio is a Switzerland-based biotechnology company specializing in regenerative medicine and therapies for rare diseases.
Major companies operating in the digestive and intestinal remedies market are Bayer AG, Abbott Laboratories, Bausch Health Companies Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Jiangzhong Pharmaceutical Co. Ltd., Johnson & Johnson Pvt. Ltd., Menarini Group, Merck Co. & KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Alfa Wassermann and Sigma-Tau, Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Chemical Pharma Co. Ltd., Evoke Pharma Inc., Ipsen SA, Ironwood Pharmaceuticals Inc., Mundipharma, Mylan NV, Norgine Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Perrigo Company, Recordati S.p.A., RedHill Biopharma Ltd., Ritter Pharmaceuticals Inc., Salix Pharmaceuticals Inc.
North America was the largest region in the digestive and intestinal remedies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digestive and intestinal remedies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digestive and intestinal remedies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The digestive and intestinal remedies market consists of sales of antacids, prokinetic agents, laxatives, antidiarrheal agents, generic enzymes. Values in this market are factory gate values that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Digestive and Intestinal Remedies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses digestive and intestinal remedies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digestive and intestinal remedies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digestive and intestinal remedies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.